NewAmsterdam Pharma (NAMS) Share-based Compensation (2022 - 2026)

NewAmsterdam Pharma has reported Share-based Compensation for 4 years, with the latest figure at $18.0 million in Q1 2026.

• Quarterly Share-based Compensation rose 18.33% year-over-year to $18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.2 million (up 52.06% YoY) and the FY2025 annual result came in at $59.4 million, up 76.76% from the prior year.
• Share-based Compensation improved to $18.0 million in Q1 2026 per NAMS's latest filing, from $14.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $18.0 million in Q1 2026 and troughed at $5.4 million in Q3 2023.
• A 4-year average of $10.4 million and a median of $8.3 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation climbed 3.97% in 2024, then jumped 92.13% in 2025.
• Over 4 years, Share-based Compensation stood at $6.0 million in 2023, then soared by 56.76% to $9.4 million in 2024, then surged by 48.94% to $14.0 million in 2025, then gained by 28.37% to $18.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $18.0 million, $14.0 million, and $15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.